The key finding
Intestinal microbiota transplant (IMT) has emerged as a safe and effective treatment for recurrent Clostridioides difficile infection (rCDI), particularly when traditional antibiotics fail. This 2025 review examines the current state of IMT access across Europe, with specific focus on Portugal, and highlights how structured intestinal microbiota banks (IMBs) could bridge the gap between proven efficacy and practical availability. The authors found that despite IMT’s demonstrated benefits for rCDI, access remains severely limited due to safety concerns, logistical challenges, and lack of standardized guidance for implementation.
What the study looked like
This was a narrative review analyzing the current landscape of IMT implementation across Europe, particularly examining how intestinal microbiota banks operate and could expand access to this treatment. The authors surveyed existing IMBs throughout Europe and assessed the barriers preventing wider adoption of IMT for rCDI treatment. Rather than testing patients directly, this review synthesized existing evidence on IMT efficacy and safety, then mapped out the infrastructure needed to deliver this therapy at scale. The focus encompassed both the clinical evidence supporting IMT for treating recurrent C. difficile infections and the practical challenges of establishing centralized facilities that can collect, screen, process, and distribute microbiota preparations safely. The review paid particular attention to Portugal’s position in developing such infrastructure and compared it to more established programs elsewhere in Europe.
Why researchers think this happened
The authors argue that IMT works by recolonizing the gut with diverse, healthy bacterial communities that can outcompete and suppress Clostridioides difficile. When antibiotics fail or lead to recurring infections, the gut microbiome becomes severely disrupted, creating an environment where C. difficile thrives. Traditional antibiotic treatment can paradoxically worsen this problem by further damaging beneficial bacteria. The researchers emphasize that while IMT has proven effective for rCDI, the therapy remains inaccessible largely due to systemic rather than scientific barriers. The lack of organized microbiota banks means hospitals struggle to source, verify, and prepare suitable donor material safely. Without standardized protocols and centralized facilities, each institution must navigate complex screening procedures, storage requirements, and quality control measures independently. The review suggests that Europe needs a coordinated strategy to establish IMBs as specialized repositories that can handle these technical demands, similar to blood banks, making IMT as accessible as other established therapies.
How to read this carefully
As a narrative review rather than original research, this paper synthesizes existing knowledge rather than presenting new clinical data. The authors advocate for expanded IMT access, which means readers should consider that the review may emphasize benefits while potentially understating remaining uncertainties. While IMT shows strong evidence for rCDI specifically, the review doesn’t extensively discuss situations where it might not work or potential long-term risks that could emerge with wider use. The European and Portuguese focus means the infrastructure challenges and solutions discussed may not directly translate to other healthcare systems. Additionally, this review addresses the organizational and logistical barriers to IMT access but doesn’t quantify exactly how many patients currently lack access or what percentage might benefit. The call for awareness-raising among healthcare providers and the public should be understood as part of an advocacy position for expanding this therapy’s availability.
What this means for everyday life
If you or someone you know has experienced recurring C. difficile infections that don’t respond to antibiotics, it’s worth knowing that IMT exists as a treatment option, even if it’s not yet widely available. The review suggests asking healthcare providers about access to microbiota transplant programs, particularly if you’ve had multiple recurrences. However, this therapy is specifically linked to recurrent CDI rather than being a general solution for digestive issues. For broader context, this review highlights how emerging treatments can remain trapped in a gap between scientific validation and practical availability due to infrastructure limitations. As countries like Portugal work to establish organized microbiota banks, access may gradually improve, but the timeline remains uncertain. Given the serious impact that recurrent C. difficile infection can have on quality of life, understanding that IMT is an evidence-based option—and advocating for its availability—might help patients have more informed conversations with their doctors about treatment possibilities when standard approaches have been exhausted.